Recombinant protein drugs are intimately associated with the impressivesuccess story of the Biotech Industry during the past thirty years, someof them belonging to the most successful pharmaceutical products. Morethan thirty different proteins are available for a variety of clinicalapplications, over 300 proteins are presently being evaluated inclinical trials.In this new volume of the MDT series, historical, technical and clinicalaspects of recombinant protein drug discovery and development arepresented, covering past, present and future highlights. Leadingscientists and co-founders of early Biotech companies describe technicalbreakthroughs and the fascinating story of pioneering discoveries, aswell as the long way of translating them into products and business.Therefore, this book represents an exciting documentation of thebeginning of a new era in the pharmaceutical industry. In addition,scientists from basic research, clinic and industry actively involved innew developments discuss...Recombinant protein drugs are intimately associated with the impressivesuccess story of the Biotech Industry during the past thirty years, someof them belonging to the most successful pharmaceutical products. Morethan thirty different proteins are available for a variety of clinicalapplications, over 300 proteins are presently being evaluated inclinical trials.In this new volume of the MDT series, historical, technical and clinicalaspects of recombinant protein drug discovery and development arepresented, covering past, present and future highlights. Leadingscientists and co-founders of early Biotech companies describe technicalbreakthroughs and the fascinating story of pioneering discoveries, aswell as the long way of translating them into products and business.Therefore, this book represents an exciting documentation of thebeginning of a new era in the pharmaceutical industry. In addition,scientists from basic research, clinic and industry actively involved innew developments discl£Ý